These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 25713333)

  • 21. Role of the androgen receptor in triple-negative breast cancer.
    Rampurwala M; Wisinski KB; O'Regan R
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of activated androgen receptor in cofilin phospho-regulation depends on the molecular subtype of TNBC cell line and actin assembly dynamics.
    Tahtamouni L; Alzghoul A; Alderfer S; Sun J; Ahram M; Prasad A; Bamburg J
    PLoS One; 2022; 17(12):e0279746. PubMed ID: 36584207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR
    Lehmann BD; Abramson VG; Sanders ME; Mayer EL; Haddad TC; Nanda R; Van Poznak C; Storniolo AM; Nangia JR; Gonzalez-Ericsson PI; Sanchez V; Johnson KN; Abramson RG; Chen SC; Shyr Y; Arteaga CL; Wolff AC; Pietenpol JA;
    Clin Cancer Res; 2020 May; 26(9):2111-2123. PubMed ID: 31822498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Positive Feedback Loop Between TGFβ and Androgen Receptor Supports Triple-negative Breast Cancer Anoikis Resistance.
    Rosas E; Roberts JT; O'Neill KI; Christenson JL; Williams MM; Hanamura T; Spoelstra NS; Vahrenkamp JM; Gertz J; Richer JK
    Endocrinology; 2021 Feb; 162(2):. PubMed ID: 33294922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
    Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA
    Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.
    Cuenca-López MD; Montero JC; Morales JC; Prat A; Pandiella A; Ocana A
    BMC Cancer; 2014 Apr; 14():302. PubMed ID: 24779793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.
    Asghar US; Barr AR; Cutts R; Beaney M; Babina I; Sampath D; Giltnane J; Lacap JA; Crocker L; Young A; Pearson A; Herrera-Abreu MT; Bakal C; Turner NC
    Clin Cancer Res; 2017 Sep; 23(18):5561-5572. PubMed ID: 28606920
    [No Abstract]   [Full Text] [Related]  

  • 29. The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer.
    Shen Y; Yang F; Zhang W; Song W; Liu Y; Guan X
    Cell Physiol Biochem; 2017; 43(5):2047-2061. PubMed ID: 29059676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
    Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
    Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer.
    He L; Du Z; Xiong X; Ma H; Zhu Z; Gao H; Cao J; Li T; Li H; Yang K; Chen G; Richer JK; Gu H
    Sci Rep; 2017 Nov; 7(1):14584. PubMed ID: 29109513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling.
    Narayanan R; Ahn S; Cheney MD; Yepuru M; Miller DD; Steiner MS; Dalton JT
    PLoS One; 2014; 9(7):e103202. PubMed ID: 25072326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction.
    Sang M; Meng L; Ma C; Liu S; Sang M; Chang S; Liu F; Lian Y; Geng C
    Biomed Pharmacother; 2019 Mar; 111():169-177. PubMed ID: 30580238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
    Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
    Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.
    Gerratana L; Basile D; Buono G; De Placido S; Giuliano M; Minichillo S; Coinu A; Martorana F; De Santo I; Del Mastro L; De Laurentiis M; Puglisi F; Arpino G
    Cancer Treat Rev; 2018 Jul; 68():102-110. PubMed ID: 29940524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features.
    Vtorushin S; Dulesova A; Krakhmal N
    J Zhejiang Univ Sci B; 2022 Aug; 23(8):617-624. PubMed ID: 35953756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide.
    Xia X; Huang C; Liao Y; Liu Y; He J; Guo Z; Jiang L; Wang X; Liu J; Huang H
    J Exp Clin Cancer Res; 2019 May; 38(1):220. PubMed ID: 31126320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RUNX1 Is Regulated by Androgen Receptor to Promote Cancer Stem Markers and Chemotherapy Resistance in Triple Negative Breast Cancer.
    Fernández NB; Sosa SM; Roberts JT; Recouvreux MS; Rocha-Viegas L; Christenson JL; Spoelstra NS; Couto FL; Raimondi AR; Richer JK; Rubinstein N
    Cells; 2023 Jan; 12(3):. PubMed ID: 36766786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness".
    Lim B; Seth S; Yam C; Huo L; Fujii T; Lee J; Bassett R; Nasser S; Ravenberg L; White J; Clayborn A; Guerra G; Litton JK; Damodaran S; Layman R; Valero V; Tripathy D; Lewis M; Dobrolecki LE; Lei J; Candelaria R; Arun B; Rauch G; Zhao L; Zhang J; Ding Q; Symmans WF; Chang JT; Thompson AM; Moulder SL; Ueno NT
    Cell Rep Med; 2024 Jun; 5(6):101595. PubMed ID: 38838676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.